Intestinal microbiota composition of children with infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and multisystem inflammatory syndrome (MIS-C)

Abstract

Microbiota composition may play a role in the development, prognosis, or post-infection of COVID-19. There are studies evaluating the microbiota composition at the time of diagnosis and during the course of COVID-19, especially in adults, while studies in children are limited and no study available in children with multisystem inflammatory syndrome in children (MIS-C). This study was planned to compare intestinal microbiota composition in children diagnosed with MIS-C and acute COVID-19 infection with healthy children. In this prospective multicenter study, 25 children diagnosed with MIS-C, 20 with COVID-19 infection, and 19 healthy children were included. Intestinal microbiota composition was evaluated by 16 s rRNA gene sequencing. We observed changes of diversity, richness, and composition of intestinal microbiota in MIS-C cases compared to COVID-19 cases and in the healthy controls. The Shannon index was higher in the MIS-C group than the healthy controls ( p < 0.01). At phylum level, in the MIS-C group, a significantly higher relative abundance of Bacteroidetes and lower abundance of Firmicutes was found compared to the control group. Intestinal microbiota composition changed in MIS-C cases compared to COVID-19 and healthy controls, and Faecalibacterium prausnitzii decreased; Bacteroides uniformis , Bacteroides plebeius , Clostridium ramosum , Eubacterium dolichum , Eggerthella lenta , Bacillus thermoamylovorans , Prevotella tannerae , and Bacteroides coprophilus were dominant in children with MIS-C. At species level, we observed decreased Faecalibacterium prausnitzii , and increased Eubacterium dolichum , Eggerthella lenta , and Bacillus thermoamylovorans in children with MIS-C and increased Bifidobacterium adolescentis and Dorea formicigenerasus in the COVID-19 group. Our study is the first to evaluate the microbiota composition in MIS-C cases. There is a substantial change in the composition of the gut microbiota: (1) reduction of F. prausnitzii in children with MIS-C and COVID-19; (2) an increase of Eggerthella lenta which is related with autoimmunity; and (3) the predominance of E. dolichum is associated with metabolic dysfunctions and obesity in children with MIS-C. Conclusions : Alterations of the intestinal microbiota might be part of pathogenesis of predisposing factor for MIS-C. It would be beneficial to conduct more extensive studies on the cause-effect relationship of these changes in microbiota composition and their effects on long-term prognosis. What is Known: • Mi...

Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications

“…Multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 has been increasingly recognized 47 . Interestingly, substantial changes in the composition of the gut microbiota were found in children with MIS-C ( n = 25) and COVID-19 ( n = 20), including a reduction of Faecalibacterium prausnitzii 48 . Nevertheless, whether the development of MIS-C might, in part, be attributed to COVID-19-related microbial dysbiosis remains unclear.…”

A cursed goodbye kiss from severe acute respiratory syndrome-coronavirus-2 to its pediatric hosts: multisystem inflammatory syndrome in children

“…The question of why a minority of infected children develop MIS-C is not known. Comorbidities such as obesity, hemophagocytic lymphohistiocytosis (HLH)-related gene mutations, some rare inborn immunity disorders, microbiota disruptions, and low socioeconomic status were proposed to be risk factors [22 ▪ ,23,24 ▪▪ ,25,26,27 ▪▪ ,28 ▪▪ ]. These findings suggest a host susceptibility to MIS-C composed of intrinsic and environmental factors.…”

Alterations of the gut microbiota in coronavirus disease 2019 and its therapeutic potential

“…Gut dysbiosis in COVID-19 patients has received widespread attention in recent years (Table 1 )[ 10 , 12 , 15 - 22 ]. The gut microbiota is significantly altered in COVID-19 patients receiving and not receiving medication compared to that in non-COVID-19 individuals[ 12 ].…”